牛牛AI助理已提取核心訊息
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
On January 19, 2024, Altamira Therapeutics Ltd. announced the initiation of an At the Market Offering Agreement with H.C. Wainwright & Co., LLC, to offer and sell its common shares at a total value of up to $1.66 million. The sales will be conducted on an 'at the market' basis, meaning they will be sold at prevailing market prices through the Nasdaq Capital Market or other trading platforms. H.C. Wainwright & Co. will receive a commission of 3.0% on the gross sales price of the shares sold. The offering is not bound by minimum sale requirements, and the total number of shares sold and the net proceeds to Altamira Therapeutics are not yet determinable. The offering will conclude once the total sales reach $1.66 million or upon termination of the agreement by either party. This follows the company's termination of a previous at-the-market offering program with A.G.P./Alliance Global Partners in December 2023, where approximately $13.06 million worth of common shares were sold.
2024年1月19日，Altamira Therapeutics Ltd.宣佈與H.C. Wainwright & Co., LLC啓動市場發行協議，以發行和出售總價值不超過166萬美元的普通股。銷售將在 “在市場上” 的基礎上進行，這意味着它們將通過納斯達克資本市場或其他交易平台以現行市場價格出售。H.C. Wainwright & Co. 將獲得按所售股票總銷售價格3.0％的佣金。此次發行不受最低銷售要求的約束，出售給Altamira Therapeutics的股票總數和淨收益尚無法確定。一旦總銷售額達到166萬美元或任何一方終止協議，此次發行將結束。在此之前，該公司於2023年12月終止了先前與A.G.P./Alliance Global Partners的市場發行計劃，該計劃出售了價值約1,306萬美元的普通股。
2024年1月19日，Altamira Therapeutics Ltd.宣佈與H.C. Wainwright & Co., LLC啓動市場發行協議，以發行和出售總價值不超過166萬美元的普通股。銷售將在 “在市場上” 的基礎上進行，這意味着它們將通過納斯達克資本市場或其他交易平台以現行市場價格出售。H.C. Wainwright & Co. 將獲得按所售股票總銷售價格3.0％的佣金。此次發行不受最低銷售要求的約束，出售給Altamira Therapeutics的股票總數和淨收益尚無法確定。一旦總銷售額達到166萬美元或任何一方終止協議，此次發行將結束。在此之前，該公司於2023年12月終止了先前與A.G.P./Alliance Global Partners的市場發行計劃，該計劃出售了價值約1,306萬美元的普通股。
有用
沒用